Log in

Association of Physician Assistants in Cardiology

  • Home
  • Omega 3 EPA - REDUCE IT study topline results

Omega 3 EPA - REDUCE IT study topline results

2 Oct 2018 5:36 PM | Viet Le (Administrator)

In light of recent results from reported at ESC 2018 from the ASCEND study, demonstrating no benefit with use of nearly 1 gram of Omega 3 supplementation in over 15,000 patients with diabetes and no CVD history (reported here: https://www.healio.com/cardiology/chd-prevention/news/online/%7B46e8e395-9a84-4ad9-bd94-d9e82c1cae3a%7D/ascend-aspirin-omega-3-supplements-fail-for-primary-prevention-in-diabetes), it appeared yet one more nail in the coffin of Omega 3 use for CVD risk reduction.

Amarin has reported topline results for the REDUCE-IT study which is a double-blinded randomized control trial looking at the addition of 4 grams of Icosapent ethyl (Vascepa; EPA) on top of statin therapy in a "high-risk" primary prevention cohort of over 8,000 individuals, with median follow-up of 4.9 years. There was a statistically significant 25% reduction in the composite cardiovascular endpoint (first occurrence of major adverse CV events, including CV death, nonfatal MI, nonfatal stroke, coronary revascularization or unstable angina requiring hospitalization).  Read below:

Image result for reduce it trial


Our Mission

To enhance the personal and professional growth of its constituent members and all Physician Assistants practicing in the Cardiology specialty through educational opportunities, community involvement, and political representation and advocacy.

Get In Touch With Us!


Copyright © Association of Physician Assistants in Cardiology
Powered by Wild Apricot Membership Software